Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Fenretinide
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Fenretinide for COVID-19
1
study with
351
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Fenretinide studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Fenretinide
reduces riskIncreased risk → |
May 30 2024 |
et al., NCT04417257 | RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease |
| 44% higher mortality (p=0.34). RCT 125 hospitalized COVID-19 patients showing no significant benefits with fenretinide (LAU-7b). | ||
